Hypoprothrombinemia (factor II deficiency): Report of a case and review of literature

Rahimi, Abdollah; Philbert, Rawle; Willoughby, J. Hamil; Jackman, Dudley S.

doi:10.1016/0278-2391(91)90273-o

Cited by 2 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…Patients with congenital hypoprothrombinaemia usually respond to this modality of therapy, however, if the patient has inhibitors to factor II, either because of previous transfusion or secondary to LA, they usually do not respond to replacement therapy, and in the latter case, immunosuppressive therapy is considered to be the primary treatment modality ( Simel et al . 1987 ; Small 1988; Rahimi et al . 1991 ; Bernini et al .…”

Section: Discussionmentioning

confidence: 99%

“…Hypoprothrombinaemia, either congenital or acquired, is rare. The treatment of the congenital type is mainly by replacement therapy with fresh frozen plasma or prothrombin complex, and anti-fibrinolytic agents may be used in mild cases (Rahimi et al 1991). The first line of treatment of patients with hypoprothrombinaemia with active bleeding and prolonged PT and PTT is replacement therapy with fresh frozen plasma, with or without vitamin K, and antifibrinolytic agents.…”

Section: Discussionmentioning

confidence: 99%

“…The first line of treatment of patients with hypoprothrombinaemia with active bleeding and prolonged PT and PTT is replacement therapy with fresh frozen plasma, with or without vitamin K, and antifibrinolytic agents. Patients with congenital hypoprothrombinaemia usually respond to this modality of therapy, however, if the patient has inhibitors to factor II, either because of previous transfusion or secondary to LA, they usually do not respond to replacement therapy, and in the latter case, immunosuppressive therapy is considered to be the primary treatment modality (Simel et al 1987;Small 1988;Rahimi et al 1991;Bernini et al 1993). The present patient did not have the minimum criteria required to diagnose SLE upon presentation (the prolonged PT and PTT which did not correct when mixed with normal plasma indicated the presence of inhibitors such as LA, which was later confirmed by appropriate tests), and this is why she did not respond to the initial replacement therapy.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Systemic lupus erythematosus presenting with haemorrhagic manifestation

Ayoub¹,

Aljurf²,

Nounou

et al. 1999

Clinical &Amp; Laboratory Haematology

View full text Add to dashboard Cite

A 26‐year‐old female presented with an episode of severe mucus membrane bleeding. Investigations revealed prolonged prothrombin time (PT), and partial thromboplastin time (PTT), normal thrombin time (TT) and reptilase time, thrombocytopenia, a positive test for lupus anticoagulant (LA), as well as anti‐cardiolipin antibodies (ACL). A toxicology screen for toxic drugs and coumadin was negative. Coagulation factor assays revealed low levels for factor II and XII. Low level inhibitor to factor II was demonstrated. Patient had a negative VDRL test and positive anti‐nuclear antibodies (ANA). The diagnosis of acquired hypoprothrombinaemia secondary to circulating inhibitor induced by LA was made, and then the patient was started on prednisone, which led to cessation of the bleeding and normalization of PT and PTT, as well as an increase of factor II and factor XII levels. A few months later, the patient developed arthralgia and alopecia, and antibodies against double‐stranded DNA were detected, and the diagnosis of systemic lupus erythematosis (SLE) was confirmed. The patient continued to have mild prolongation of PT and PTT while on a low dose of prednisone, but she had no bleeding symptoms. A computed tomography scan of the brain was carried out for unexplained central nervous system (CNS) symptoms, and it revealed mild hydrocephalus, which was thought to be part of the CNS manifestations of SLE. It was concluded that patients with SLE may present with haemostatic defects that are a result of either platelet‐related causes (quantitative or qualitative) or coagulation factor deficiency secondary to circulating inhibitor, or both, in the absence of other features of SLE which may appear later.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Systemic lupus erythematosus presenting with haemorrhagic manifestation

Ayoub¹,

Aljurf²,

Nounou

et al. 1999

Clinical &Amp; Laboratory Haematology

View full text Add to dashboard Cite

show abstract

Perioperative Recommendations for Corneal Refractive Surgery Patients With Inherited Bleeding Disorders

Moshirfar,

Reynolds,

Moin

et al. 2024

Cornea

View full text Add to dashboard Cite

Purpose: To synthesize the current literature regarding patients with inherited bleeding disorders and suggest comprehensive evaluation and preoperative recommendations for these patients before undergoing corneal refractive surgery. Methods: The literature search was conducted through PubMed, Embase, and Google Scholar databases for publications through January 4, 2024 for reports of ocular bleeding manifestations in patients with inherited bleeding disorders and reports of patients without a history of bleeding disorders who had intraoperative or postoperative hemorrhagic complications with corneal refractive surgery. Additional cases from the literature and a retrospective chart review at a corneal practice were obtained describing patients with inherited bleeding disorders who underwent corneal refractive surgery. Results: Four articles were found detailing ocular bleeding manifestations in patients with inherited bleeding disorders who underwent ocular surgery other than corneal refractive surgery. Thirty articles were found detailing intraoperative and postoperative bleeding manifestations in patients without a history of inherited bleeding disorders who underwent corneal refractive surgery. Eight cases (3 patients from the literature search and 5 patients from a retrospective chart review) were found regarding patients with inherited bleeding disorders who underwent corneal refractive surgery. Conclusions: For corneal refractive surgery with topical anesthesia, the perioperative risk and need for any hemostasis intervention in individuals with an inherited bleeding disorder depends on the type of disorder, status of preoperative factor level concentrations, or a prior history of bleeding. If required, clotting factor optimization should be tailored to each candidate on a case-by-case basis.

show abstract

Hypoprothrombinemia (factor II deficiency): Report of a case and review of literature

Cited by 2 publications

References 20 publications

Systemic lupus erythematosus presenting with haemorrhagic manifestation

Systemic lupus erythematosus presenting with haemorrhagic manifestation

Perioperative Recommendations for Corneal Refractive Surgery Patients With Inherited Bleeding Disorders

Contact Info

Product

Resources

About